Previous Article | Next Article ![]()
Journal of Clinical Microbiology, October 2006, p. 3822-3825, Vol. 44, No. 10
0095-1137/06/$08.00+0 doi:10.1128/JCM.01232-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Centre for Infectious Diseases and Microbiology (CIDM), Institute of Clinical Pathology and Medical Research (ICPMR), Westmead, New South Wales, Australia,1 Department of Dermatology, Wuhan First Hospital, Wuhan, Hubei Province, People's Republic of China,2 Streptococcus Reference Laboratory, Institute of Environmental Science and Research Ltd., Porirua, New Zealand3
Received 15 June 2006/ Accepted 22 June 2006
|
|
|---|
|
|
|---|
Conventional serotyping (CS) was performed as described before (8). Rabbit antisera were raised at ESR, using standard methodology (WHO International Reference Centre for Streptococcus Typing, Prague, Czech Republic) and GBS serotype strains obtained from the New Zealand Reference Culture Collection Medical Section. Antisera were not raised against serotypes VI to VIII because they were very rare in New Zealand at the time. Antisera were checked for specificity against type-specific antigens for all strains.
mPCR/RLB primers and probes from our previous studies (2, 9) were combined together in the same mPCR/RLB assay for this study. The 17 targets were one GBS species-specific target (cfb), nine MS-specific targets (serotypes Ia to VIII) (2, 9), and seven PGP-specific targets (genes encoding Bca/C
, Rib, Alp1 [Alp1/Alp5/Epsilon], Alp2, Alp3, Alp4, and the immunoglobulin A binding protein Bac/Cß) (9). In all, there were 33 primers (alp2 and alp3 share the same forward primer) and 34 probes (two for each target). mPCR/RLB was performed as previously described (2, 9), except that for mPCR, the 33 primers were combined in the same tube with 0.2 µl (1 unit) rather than 0.1 µl (0.5 unit) QIAGEN Hotstar Taq polymerase (5 units/µl); for RLB, 17 probe pairs (see above) were used on the same membrane.
The MS and PGPs of all 27 reference strains (Table 1), as identified by the 33-primer mPCR/RLB assay, were identical to those obtained previously by PCR and sequencing (3, 4), separate MS 20-primer mPCR/RLB (2) and PGP 13-primer mPCR/RLB (9) assays, and CS for those that were serotypeable (25 reference strains) and for which protein type results were available (9 reference strains). The CS results and mPCR/RLB results for 551 clinical isolates are shown in Table 2. mPCR/RLB results for 40 isolates from 1997 to 1998 are shown in Fig. 1.
|
View this table: [in a new window] |
TABLE 1. Results of CS, MS identification based on PCR and sequencing, and mPCR/RLB for 27 reference strains
|
|
View this table: [in a new window] |
TABLE 2. Comparison of CS for capsular type with mPCR/RLB results for 551 GBS clinical isolates
|
![]() View larger version (44K): [in a new window] |
FIG. 1. Results of mPCR/RLB assay for 40 consecutive isolates. Sample 35 was buffer, which was used as a negative control. Probes sag59Sp and sag190Ap are group B streptococcus specific. Molecular serotype probes are named according to the corresponding serotype, the cps gene target (e.g., cpsH, cpsK, etc.), and whether the probe is sense (S) or antisense (A). Protein gene probes are named for the corresponding protein, except for GBS1716Ap and GBS1716Sp, which are the sense (S) and antisense (A) probes targeting the Cß gene (bac) (3, 4).
|
The majority of isolates (401 [73%]) were nontypeable using antisera against the R and C antigens. R protein antigens were identified in 96 (17%) isolates, and C antigens were identified in 54 (10%) of 551 isolates. However, at least one protein antigen gene was identified by mPCR/RLB in 547 (99%) isolates (Table 3); bca was the most common and usually was present with another protein gene (most commonly bac), as previously reported (9). Apart from bac, protein genes were almost always mutually exclusive, except for the case of a single atypical isolate which had both bca and rib. Of the 96 isolates with R proteins, 1 had no detectable protein genes, 71 (73%) contained rib, 23 (24%) contained alp3, and 1 contained alp1. Apart from the first and last isolates, these results were consistent between CS and mPCR/RLB. Of the 54 isolates that were positive for the C protein, 34 (62%) contained alp1, 19 (35%) contained bac (of which 10 also had bca), and 1 contained alp2. Only the last result was inconsistent between CS and mPCR/RLB. As previously demonstrated, the identification of protein antigens using antisera is difficult, and cross-reactions are common (6). However, in general, isolates that express the R protein, as demonstrated using antisera, contain rib or alp3, and those that express the C protein contain alp1 or bac (C
), with or without bca (Cß) (5, 7, 9).
|
View this table: [in a new window] |
TABLE 3. Relationships between MS and PGPs for 551 GBS clinical isolates
|
Some probes reacted (usually very weakly) with amplicons from more than one serotype. For example, amplicons from most MS Ia and V isolates cross-hybridized weakly with VcpsHSp and IacpsHSp, as previously described (2). However, the combined results for VcpsHAp/VcpsHSp and IacpsHAp/IacpsHSp clearly distinguished between serotypes Ia and V (Fig. 1). Otherwise, the sensitivity and specificity of mPCR/RLB were considerably better than those of CS and similar to those of individual serotype-specific PCRs for confirmed GBS isolates.
The development of multivalent conjugate GBS vaccines containing the most important serotypes and, potentially, specific GBS protein antigens is under way. Epidemiological studies and surveillance of GBS serotype and PGP distributions for different diseases, age groups, and countries and over time are needed to support vaccine development. The relatively recent emergence of serotypes VI, VII, and VIII demonstrates the ongoing evolution of GBS. Our mPCR/RLB assay for detection of MS and PGPs will provide a convenient and inexpensive tool for ongoing surveillance. The mPCR/RLB assay is easy to perform and does not require the use of expensive commercial antisera (which are available only for some serotypes) or in-house antisera, which have variable specificity and quality and frequently cross-react. The amplification products of 43 isolates can be tested simultaneously in the mPCR/RLB assay, making the assay suitable for high-throughput epidemiological studies of GBS (2). Because PCR detects the presence of capsular genes, it can characterize isolates with low or absent capsular expression, which are nonserotypeable by CS. The mPCR/RLB assay has enabled, for the first time, the objective, simultaneous identification of GBS capsular types and protein antigens without the need for interpretation requiring an experienced operator. It also has the potential to be used directly for clinical specimens (1).
Several isolates for which the results were controversial were kindly tested with antisera against all serotypes by Androulla Efstratiou at the WHO Collaborating Centre for Diphtheria and Streptococcal Infections, Health Protection Agency Centre for Infections, Colindale, London, United Kingdom. We thank Ilya Henner for precious help with sequencing.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»